keyword
https://read.qxmd.com/read/38536770/a-co-reactive-immunosensor-based-on-ti-3-c-2-t-x-mxene-tio-2-mos-2-hybrids-promoting-luminol-au-ni-co-ncs-electrochemiluminescence-for-cyfra-21-1-detection
#1
JOURNAL ARTICLE
Xiang Ren, Mingyue Shao, Zuoxun Xie, Xiaojian Li, Hongmin Ma, Dawei Fan, Jinxiu Zhao, Qin Wei
The construction of assays is capable of accurately detecting cytokeratin-19 (CYFRA 21-1), which is critical for the rapid diagnosis of nonsmall cell lung cancer. In this work, a novel electrochemiluminescence (ECL) immunosensor based on the co-reaction promotion of luminol@Au@Ni-Co nanocages (NCs) as ECL probe by Ti3 C2 T x MXene@TiO2 -MoS2 hybrids as co-reaction accelerator was proposed to detect CYFRA 21-1. Ni-Co NCs, as a derivative of Prussian blue analogs, can be loaded with large quantities of Au NPs, luminol, and CYFRA 21-1 secondary antibodies due to their high specific surface area...
March 27, 2024: ACS Sensors
https://read.qxmd.com/read/38536747/case-weighted-power-priors-for-hybrid-control-analyses-with-time-to-event-data
#2
JOURNAL ARTICLE
Evan Kwiatkowski, Jiawen Zhu, Xiao Li, Herbert Pang, Grazyna Lieberman, Matthew A Psioda
We develop a method for hybrid analyses that uses external controls to augment internal control arms in randomized controlled trials (RCTs) where the degree of borrowing is determined based on similarity between RCT and external control patients to account for systematic differences (e.g., unmeasured confounders). The method represents a novel extension of the power prior where discounting weights are computed separately for each external control based on compatibility with the randomized control data. The discounting weights are determined using the predictive distribution for the external controls derived via the posterior distribution for time-to-event parameters estimated from the RCT...
March 27, 2024: Biometrics
https://read.qxmd.com/read/38536706/prognostic-value-of-pretreatment-procalcitonin-and-neutrophil-lymphocyte-ratio-in-extensive-stage-small-cell-lung-cancer
#3
JOURNAL ARTICLE
Dongfang Chen, Jianlin Xu, Yizhuo Zhao, Baohui Han, Runbo Zhong
BACKGROUND: To investigate the influence of pretreatment neutrophil-to-lymphocyte ratio (NLR) and procalcitonin (PCT) on progression-free survival (PFS) in extensive-stage small-cell lung cancer (SCLC) patients. METHOD: A total of 100 extensive-stage SCLC patients were enrolled in our study. Patients were stratified according to the median values of pretreatment NLR and PCT levels: low NLR group (NLR ≤3.17), high NLR group (NLR>3.17), low PCT group (PCT ≤0...
December 31, 2024: Cancer Biology & Therapy
https://read.qxmd.com/read/38536631/the-importance-of-biomarker-testing-in-the-treatment-of-advanced-non-small-cell-lung-cancer-a-podcast
#4
JOURNAL ARTICLE
Fred R Hirsch, Chul Kim
The identification of actionable biomarkers and development of targeted therapies have revolutionized the field of lung cancer treatment. In patients with advanced non-small cell lung cancer (NSCLC), biomarker testing can inform selection of effective targeted therapies as well as avoid therapies that are less likely to be effective in certain populations. A growing number of actionable targets, including those involving EGFR, ALK, ROS1, BRAF, MET, KRAS, NTRK, RET, HER2, and PD-L1, can be identified with biomarker testing...
March 27, 2024: Oncology and Therapy
https://read.qxmd.com/read/38536543/effect-of-early-dose-reduction-of-osimertinib-on-efficacy-in-the-first-line-treatment-for-egfr-mutated-non-small-cell-lung-cancer
#5
JOURNAL ARTICLE
Tomoki Hori, Kazuhiro Yamamoto, Takefumi Ito, Shigeki Ikushima, Tomohiro Omura, Ikuko Yano
Osimertinib is used as the first-line therapy for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). However, early dose reduction is often required due to adverse events (AEs). This study aimed to evaluate the effect of early dose reduction of osimertinib on efficacy and safety. This was a retrospective study including patients with EGFR-mutated NSCLC who were started on osimertinib as the first-line therapy between August 2018 and December 2021. Patients whose doses were reduced to less than 80 mg/day within 6 months of osimertinib initiation or started at 40 mg/day were defined as the dose reduction group...
March 27, 2024: Investigational New Drugs
https://read.qxmd.com/read/38535442/natural-products-derived-from-marine-sponges-with-antitumor-potential-against-lung-cancer-a-systematic-review
#6
REVIEW
Alba Ortigosa-Palomo, Francisco Quiñonero, Raul Ortiz, Francisco Sarabia, Jose Prados, Consolación Melguizo
Non-small-cell lung cancer (NSCLC), the most commonly diagnosed cancer and the leading cause of cancer-related death worldwide, has been extensively investigated in the last decade in terms of developing new therapeutic options that increase patient survival. In this context, marine animals are a source of new, interesting bioactive molecules that have been applied to the treatment of different types of cancer. Many efforts have been made to search for new therapeutic strategies to improve the prognosis of lung cancer patients, including new bioactive compounds and cytotoxic drugs from marine sponges...
February 23, 2024: Marine Drugs
https://read.qxmd.com/read/38534959/outcomes-of-patients-with-non-small-cell-lung-cancer-and-brain-metastases-treated-with-the-upfront-single-agent-pembrolizumab-a-retrospective-and-multicentric-study-of-the-esckeyp-gfpc-cohort
#7
MULTICENTER STUDY
Simon Nannini, Florian Guisier, Hubert Curcio, Charles Ricordel, Pierre Demontrond, Safa Abdallahoui, Seyyid Baloglu, Laurent Greillier, Christos Chouaid, Roland Schott
Non-small cell lung cancer (NSCLC) is the most common cause of brain metastasis (BM). Little is known about immune checkpoint inhibitor activity in the central nervous system, especially in patients receiving monotherapy for tumors with a tumor proportion score (TPS) ≥ 50%. This noninterventional, retrospective, multicenter study, conducted with the GFPC, included treatment-naïve patients strongly positive for PD-L1 (TPS ≥ 50%) with BM receiving first-line single-agent pembrolizumab treatment between May 2017 and November 2019...
March 21, 2024: Current Oncology
https://read.qxmd.com/read/38534955/population-survival-kinetics-derived-from-clinical-trials-of-potentially-curable-lung-cancers
#8
JOURNAL ARTICLE
David J Stewart, Katherine Cole, Dominick Bosse, Stephanie Brule, Dean Fergusson, Tim Ramsay
Using digitized data from progression-free survival (PFS) and overall survival Kaplan-Meier curves, one can assess population survival kinetics through exponential decay nonlinear regression analyses. To demonstrate their utility, we analyzed PFS curves from published curative-intent trials of non-small cell lung cancer (NSCLC) adjuvant chemotherapy, adjuvant osimertinib in resected EGFR -mutant NSCLC (ADAURA trial), chemoradiotherapy for inoperable NSCLC, and limited small cell lung cancer (SCLC). These analyses permit assessment of log-linear curve shape and estimation of the proportion of patients cured, PFS half-lives for subpopulations destined to eventually relapse, and probability of eventual relapse in patients remaining progression-free at different time points...
March 20, 2024: Current Oncology
https://read.qxmd.com/read/38534949/wedge-resection-versus-stereotactic-body-radiation-therapy-for-non-small-cell-lung-cancer-tumors-%C3%A2-8-mm
#9
JOURNAL ARTICLE
Arian Mansur, Zain Saleem, Jorind Beqari, Camille Mathey-Andrews, Alexandra L Potter, James Cranor, Alexandra T Nees, Deepti Srinivasan, Margaret E Yang, Chi-Fu Jeffrey Yang, Hugh G Auchincloss
The objective of this study was to evaluate the overall survival of patients with ≤8 mm non-small cell lung cancer (NSCLC) who undergo wedge resection versus stereotactic body radiation therapy (SBRT). Kaplan-Meier analysis, multivariable Cox proportional hazards modeling, and propensity score-matched analysis were performed to evaluate the overall survival of patients with ≤8 mm NSCLC in the National Cancer Database (NCDB) from 2004 to 2017 who underwent wedge resection versus patients who underwent SBRT...
March 15, 2024: Current Oncology
https://read.qxmd.com/read/38534948/biomarker-turnaround-times-and-impact-on-treatment-decisions-in-patients-with-advanced-non-small-cell-lung-carcinoma-at-a-large-canadian-community-hospital-with-an-affiliated-regional-cancer-centre
#10
JOURNAL ARTICLE
Katelyn E Fleming, Ava Hupel, Hamid Mithoowani, Tea Lulic-Kuryllo, Mario Valdes
Background : Timely reporting of molecular biomarkers is critical in guiding optimal treatment decisions in patients with advanced non-small cell lung carcinoma (NSCLC). Any delays along the tissue or treatment pathway may be associated with suboptimal treatment/outcomes and a reduced quality of life. For many centres, biomarkers are tested off-site. Methods: A retrospective chart review of 123 patients with advanced NSCLC seen between 1 June 2021 and 30 June 2022 was conducted. With a focus on core biomarkers (PD L1, EGFR, and ALK), the outcome variables were as follows: total turnaround time (total TAT), divided into pre-laboratory, laboratory, and post-laboratory time intervals, as well as time to treatment decision (TOTD) and time to optimal systemic therapy decision (TOTSD)...
March 14, 2024: Current Oncology
https://read.qxmd.com/read/38534371/protac-mediated-dual-degradation-of-bcl-xl-and-bcl-2-is-a-highly-effective-therapeutic-strategy-in-small-cell-lung-cancer
#11
JOURNAL ARTICLE
Sajid Khan, Lin Cao, Janet Wiegand, Peiyi Zhang, Maria Zajac-Kaye, Frederic J Kaye, Guangrong Zheng, Daohong Zhou
BCL-xL and BCL-2 are validated therapeutic targets in small-cell lung cancer (SCLC). Targeting these proteins with navitoclax (formerly ABT263, a dual BCL-xL/2 inhibitor) induces dose-limiting thrombocytopenia through on-target BCL-xL inhibition in platelets. Therefore, platelet toxicity poses a barrier in advancing the clinical translation of navitoclax. We have developed a strategy to selectively target BCL-xL in tumors, while sparing platelets, by utilizing proteolysis-targeting chimeras (PROTACs) that hijack the cellular ubiquitin proteasome system for target ubiquitination and subsequent degradation...
March 17, 2024: Cells
https://read.qxmd.com/read/38533561/a-real-world-multicentre-evaluation-of-atezolizumab-plus-platinum-etoposide-chemotherapy-as-first-line-treatment-in-patients-with-extensive-stage-small-cell-lung-cancer-in-italy
#12
JOURNAL ARTICLE
Felice Musicco, Chiara Fulgenzio, Antonia La Malfa, Nicoletta Jannitti, Antonietta Vitiello, Silvia Carpano, Francesca Fusco, Federico Cappuzzo, Irene Terrenato, Isabella Sperduti, Piera Polidori, Domenico Tarantino, Lidia Di Cerbo, Marcello Pani, Valentina Isgrò, Ruggero Lasala
INTRODUCTION: The aim of this study was to analyze real-life data from a cohort of adult patients receiving atezolizumab in combination with carboplatin and etoposide for first-line treatment of ES-SCLC, in order to assess relative dose intensity (RDI), time-to-treatment discontinuation (TTD), time-to-treatment failure (TTF), progression-free survival (PFS), overall survival (OS) of treatments as well as the correlation between these outcomes. METHODS: An observational retrospective study was conducted...
March 27, 2024: Journal of Oncology Pharmacy Practice
https://read.qxmd.com/read/38533509/role-of-cd38-in-anti-tumor-immunity-of-small-cell-lung-cancer
#13
JOURNAL ARTICLE
Hirokazu Taniguchi, Shweta S Chavan, Andrew Chow, Joseph M Chan, Hiroshi Mukae, Charles M Rudin, Triparna Sen
INTRODUCTION: Immune checkpoint blockade (ICB) with or without chemotherapy has a very modest benefit in patients with small cell lung cancer (SCLC). SCLC tumors are characterized by high tumor mutation burden (TMB) and low PD-L1 expression. Therefore, TMB and PD-L1 do not serve as biomarkers of ICB response in SCLC. CD38, a transmembrane glycoprotein, mediates immunosuppression in non-small cell lung cancer (NSCLC). In this brief report, we highlight the potential role of CD38 as a probable biomarker of immunotherapy response in SCLC...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38533033/elucidating-the-anti-cancer-potential-of-cinnamomum-tamala-essential-oil-against-non-small-cell-lung-cancer-a-multifaceted-approach-involving-gc-ms-profiling-network-pharmacology-and-molecular-dynamics-simulations
#14
JOURNAL ARTICLE
Debajani Mohanty, Sucheesmita Padhee, Arpita Priyadarshini, Bibhuti Bhusan Champati, Prabhat Kumar Das, Sudipta Jena, Ambika Sahoo, Pratap Chandra Panda, Sanghamitra Nayak, Asit Ray
Cinnamomum tamala (Buch.-Ham.) T.Nees & Eberm., or Indian Bay Leaf, is a well-known traditional ayurvedic medicine used to treat various ailments. However, the molecular mechanism of action of Cinnamomum tamala essential oil (CTEO) against non-small cell lung cancer (NSCLC) remains elusive. The present study aims to decipher the molecular targets and mechanism of CTEO in treating NSCLC. GC-MS analysis detected 49 constituents; 44 successfully passed the drug-likeness screening and were identified as active compounds...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38532729/serplulimab-monotherapy-in-extensive-stage%C3%A2-small-cell-lung-cancer-with-brain-metastasis-a-case-report
#15
JOURNAL ARTICLE
Xudong Xiang, Heng Li, Bao Lei, Benchao Chen, Gaofeng Li
Small-cell lung cancer (SCLC) is an aggressive form of lung cancer with limited treatment options, especially for extensive-stage (ES) patients. We present a case of a 70-year-old male with ES-SCLC and asymptomatic brain metastasis who opted for immune monotherapy with serplulimab (an anti-PD-1 antibody). After four cycles, the patient achieved a confirmed partial response and a progression-free survival of over 1 year. Moreover, we observed a consistent decline in tumor biomarkers, and brain MRI indicated reduced metastatic activity...
March 27, 2024: Immunotherapy
https://read.qxmd.com/read/38532454/immature-central-tumor-tertiary-lymphoid-structures-are-associated-with-better-prognosis-in-non-small-cell-lung-cancer
#16
JOURNAL ARTICLE
Deng Xiaoxu, Xu Min, Cao Chengcheng
BACKGROUND & AIMS: Tertiary lymphoid structures (TLSs) are predictive biomarkers of favorable clinical outcomes and immunotherapy response in several solid malignancies, including non-small cell lung cancer (NSCLC). However, the relationship between TLSs and NSCLC prognosis has not been eludicated from the aspects of location, density, and maturity. This study aimed to investigate the clinicopathological and prognostic significance of TLSs in NSCLC. METHODS: A collection of 151 resected pulmonary nodules in patients with NSCLC was retrospectively analyzed...
March 26, 2024: BMC Pulmonary Medicine
https://read.qxmd.com/read/38532196/digital-counting-of-tissue-cells-for-molecular-analysis-the-quantum-pipeline
#17
JOURNAL ARTICLE
Vincenzo L'Imperio, Giorgio Cazzaniga, Mauro Mannino, Davide Seminati, Francesco Mascadri, Joranda Ceku, Gabriele Casati, Francesca Bono, Catarina Eloy, Elena Guerini Rocco, Chiara Frascarelli, Matteo Fassan, Umberto Malapelle, Fabio Pagni
The estimation of tumor cellular fraction (TCF) is a crucial step in predictive molecular pathology, representing an entry adequacy criterion also in the next-generation sequencing (NGS) era. However, heterogeneity of quantification practices and inter-pathologist variability hamper the robustness of its evaluation, stressing the need for more reliable results. Here, 121 routine histological samples from non-small cell lung cancer (NSCLC) cases with complete NGS profiling were used to evaluate TCF interobserver variability among three different pathologists (pTCF), developing a computational tool (cTCF) and assessing its reliability vs ground truth (GT) tumor cellularity and potential impact on the final molecular results...
March 26, 2024: Virchows Archiv: An International Journal of Pathology
https://read.qxmd.com/read/38531958/comparing-deep-learning-and-pathologist-quantification-of-cell-level-pd-l1-expression-in-non-small-cell-lung-cancer-whole-slide-images
#18
JOURNAL ARTICLE
Leander van Eekelen, Joey Spronck, Monika Looijen-Salamon, Shoko Vos, Enrico Munari, Ilaria Girolami, Albino Eccher, Balazs Acs, Ceren Boyaci, Gabriel Silva de Souza, Muradije Demirel-Andishmand, Luca Dulce Meesters, Daan Zegers, Lieke van der Woude, Willemijn Theelen, Michel van den Heuvel, Katrien Grünberg, Bram van Ginneken, Jeroen van der Laak, Francesco Ciompi
Programmed death-ligand 1 (PD-L1) expression is currently used in the clinic to assess eligibility for immune-checkpoint inhibitors via the tumor proportion score (TPS), but its efficacy is limited by high interobserver variability. Multiple papers have presented systems for the automatic quantification of TPS, but none report on the task of determining cell-level PD-L1 expression and often reserve their evaluation to a single PD-L1 monoclonal antibody or clinical center. In this paper, we report on a deep learning algorithm for detecting PD-L1 negative and positive tumor cells at a cellular level and evaluate it on a cell-level reference standard established by six readers on a multi-centric, multi PD-L1 assay dataset...
March 26, 2024: Scientific Reports
https://read.qxmd.com/read/38531888/background-and-clinical-significance-of-biomarker-based-patient-enrichment-in-non-small-cell-lung-cancer-drug-development
#19
JOURNAL ARTICLE
Kenji Harada, Shunsuke Ono
Pharmaceutical companies have adopted biomarker-based enrichment (personalized) strategies to improve research and development productivity. We explored the background in which personalized strategies are adopted and examined whether their adoption is linked to improved efficacy of new drugs approved for non-small cell lung cancer (NSCLC) by US Food and Drug Administration (FDA). We extracted data from the first labels of drugs approved for NSCLC between May 2003 and February 2021, and performed a qualitative comparative analysis and meta-analysis...
March 26, 2024: Scientific Reports
https://read.qxmd.com/read/38531883/polygenic-risk-score-for-ulcerative-colitis-predicts-immune-checkpoint-inhibitor-mediated-colitis
#20
JOURNAL ARTICLE
Pooja Middha, Rohit Thummalapalli, Michael J Betti, Lydia Yao, Zoe Quandt, Karmugi Balaratnam, Cosmin A Bejan, Eduardo Cardenas, Christina J Falcon, David M Faleck, Matthew A Gubens, Scott Huntsman, Douglas B Johnson, Linda Kachuri, Khaleeq Khan, Min Li, Christine M Lovly, Megan H Murray, Devalben Patel, Kristin Werking, Yaomin Xu, Luna Jia Zhan, Justin M Balko, Geoffrey Liu, Melinda C Aldrich, Adam J Schoenfeld, Elad Ziv
Immune checkpoint inhibitor-mediated colitis (IMC) is a common adverse event of treatment with immune checkpoint inhibitors (ICI). We hypothesize that genetic susceptibility to Crohn's disease (CD) and ulcerative colitis (UC) predisposes to IMC. In this study, we first develop a polygenic risk scores for CD (PRSCD ) and UC (PRSUC ) in cancer-free individuals and then test these PRSs on IMC in a cohort of 1316 patients with ICI-treated non-small cell lung cancer and perform a replication in 873 ICI-treated pan-cancer patients...
March 26, 2024: Nature Communications
keyword
keyword
37726
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.